BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33004238)

  • 1. Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain.
    Monteagudo M; Nuñez A; Solntseva I; Dhalwani N; Booth A; Barrecheguren M; Lambrelli D; Miravitlles M
    Arch Bronconeumol (Engl Ed); 2021 Mar; 57(3):205-213. PubMed ID: 33004238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing pathways to triple therapy in patients with chronic obstructive pulmonary disease in the United States.
    Schabert V; Shah S; Holmgren U; Cabrera C
    Ther Adv Respir Dis; 2021; 15():17534666211001018. PubMed ID: 33866875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD.
    Monteagudo M; Barrecheguren M; Solntseva I; Dhalwani N; Booth A; Nuñez A; Lambrelli D; Miravitlles M
    NPJ Prim Care Respir Med; 2021 Mar; 31(1):16. PubMed ID: 33753747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.
    Brusselle G; Price D; Gruffydd-Jones K; Miravitlles M; Keininger DL; Stewart R; Baldwin M; Jones RC
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2207-17. PubMed ID: 26527869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study.
    Barrecheguren M; Monteagudo M; Ferrer J; Borrell E; Llor C; Esquinas C; Miravitlles M
    Respir Med; 2016 Feb; 111():47-53. PubMed ID: 26758585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
    Scalone G; Nava S; Ventrella F; Bussoli G; Catapano GA; Pennisi A; Dadduzio F; Schino P; Pela R; Bartezaghi M; Morini P; Porpiglia PA; Muscianisi E;
    Pulm Pharmacol Ther; 2018 Dec; 53():68-77. PubMed ID: 30193866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care.
    Thomas M; Radwan A; Stonham C; Marshall S
    COPD; 2014 Jun; 11(3):300-9. PubMed ID: 24152210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting.
    Bogart M; Glassberg MB; Reinsch T; Stanford RH
    Respir Med; 2018 Dec; 145():138-144. PubMed ID: 30509702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice.
    Sansbury LB; Bains C; Lipson DA; Ismaila AS; Landis SH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1255-1264. PubMed ID: 33986594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study.
    Monteagudo M; Roset M; Rodriguez-Blanco T; Muñoz L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1145-1152. PubMed ID: 28442901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand.
    Xu X; Milea D; Navarro Rojas AA; Braganza A; Holbrook T; Marett B; Young R; Scott RJ; Gribben B
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1835-1850. PubMed ID: 34177262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
    Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database.
    Calabria S; Ronconi G; Dondi L; Piccinni C; Pedrini A; Esposito I; Pistelli R; Martini N
    Pulm Pharmacol Ther; 2020 Apr; 61():101904. PubMed ID: 32092473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study.
    Di Marco F; Santus P; Terraneo S; Peruzzi E; Muscianisi E; Ripellino C; Pegoraro V
    NPJ Prim Care Respir Med; 2017 Sep; 27(1):51. PubMed ID: 28883469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
    Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database.
    Milea D; Yeo SH; Nam Y; Navarro Rojas AA; Shantakumar S; Beale J; Marett B; Young RP; Scott RJ; Gribben B
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1075-1091. PubMed ID: 33907394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.